Arcutis Biotherapeutics, Inc. ARQT Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 90.2%0.0pp | 90.3%-1.4pp | 91.6%+12.1pp | 79.5%— | |
| Efficiency | |||||
| Asset turnover | 1×+0.4× | 0.6×+0.4× | 0.2×+0.1× | 0×— | |
| Liquidity | |||||
| Current ratio | 3.2×-1.0× | 4.1×-2.9× | 7.1×-4.5× | 11.6×-0.5× | |
| Leverage | |||||
| Debt-to-equity | 0.6×-0.1× | 0.7×-1.6× | 2.3×+1.4× | 1×+0.7× | |
| Per Share | |||||
| Book value per share | $1.49+14.3% | $1.30+1.8% | $1.28-66.4% | $3.81-36.8% | |
| Valuation | |||||
| Market capitalization | $3.56B+118% | $1.63B+435% | $304.85M-66.2% | $901.73M-13.6% | |
| Price / sales | 9.5×+1.2× | 8.3×+3.2× | 5.1×-240× | 244.6×— | |
| Price / book | 18.8×+8.4× | 10.3×+6.9× | 3.4×-0.9× | 4.3×+0.8× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Arcutis Biotherapeutics, Inc.'s profit margins?
- Arcutis Biotherapeutics, Inc. (ARQT) runs a 90.9% gross margin and a -12.0% operating margin, with a -13.9% net margin.
- Where do Arcutis Biotherapeutics, Inc.'s ratios come from?
- Every ratio is computed from Arcutis Biotherapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.